(E)-2-(3,4,5-trimethoxystyryl)benzo[b]thiophene | 1415089-14-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: (E)-2-(3,4,5-trimethoxystyryl)benzo[b]thiophene
• 英文别名: 2-[(E)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1-benzothiophene
• CAS: 1415089-14-3
• 化学式: C₁₉H₁₈O₃S
• 分子量: 326.416
• InChiKey: ZCDBCYWQRBDFOL-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  55.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-苯并噻酚-2-羧醛 、 三苯基-(3,4,5-三甲氧基-苄基)-溴化膦 在 sodium methylate 作用下， 以 甲醇 为溶剂， 生成 (E)-2-(3,4,5-trimethoxystyryl)benzo[b]thiophene
  参考文献：
  名称：

  Heteroaromatic analogs of the resveratrol analog DMU-212 as potent anti-cancer agents

  摘要：

  Heteroaromatic analogs of DMU-212 (8-15) have been synthesized and evaluated for their anti-cancer activity against a panel of 60 human cancer cell lines. These novel analogs contain a trans-3,4,5-trimethoxystyryl moiety attached to the C2 position of indole, benzofuran, benzothiazole or benzothiophene ring (8, 11, 13 and 14, respectively) and showed potent growth inhibition in 85% of the cancer cell lines examined, with GI(50) values <1 mu M. Interestingly, trans-3,4-and trans-3,5-dimethoxystyryl DMU-212 analogs 9, 10, 12 and 15 exhibited significantly less growth inhibition than their 3,4,5-trimethoxystyryl counterparts, suggesting that the trans-3,4,5-trimethoxystyryl moiety is an essential structural element for the potent anti-cancer activity of these heterocyclic DMU-212 analogs. Molecular modeling studies showed that the four most active compounds (8, 11, 13 and 14) all bind to the colchicine binding site on tubulin, and that their binding modes are similar to that of DMU-212. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.05.019

文献信息

• Synthesis of (Z) isomers of benzoheterocyclic derivatives of combretastatin A-4: a comparative study of several methods
  作者：Thi Thanh Binh Nguyen、Thierry Lomberget、Ngoc Chau Tran、Roland Barret

  DOI：10.1016/j.tet.2013.01.005

  日期：2013.3

  monobromoalkene, a combination of hydrosilylation/vinylsilane hydrolysis and a palladium-catalyzed semi-hydrogenation step, using DMF/KOH as the hydrogen source. Our studies led us to prepare a series of diarylacetylene derivatives via a Sonogashira coupling reaction, and also to find out a copper-free basic cyclization leading to benzo[b]thiophenes. The final choice for the synthesis method of 1 strongly depends

  研究了几种制备（Z）三甲氧基苯乙烯衍生物1的方法。在发现Wittig反应导致不满意的结果后，考虑了三种不同的策略：使用DMF / KOH作为氢源的Suzuki偶联与立体定义的单溴烯烃，氢化硅烷化/乙烯基硅烷水解和钯催化的半氢化步骤的组合。我们的研究使我们通过Sonogashira偶联反应制备了一系列二芳基乙炔衍生物，并且发现了无铜的碱性环化反应，从而生成了苯并[ b ]噻吩。1的合成方法的最终选择 强烈依赖于目标化合物，但通常应优先选择避免使用有毒锡还原剂的半氢化反应。
• Synthesis and biological evaluation of novel heterocyclic derivatives of combretastatin A-4
  作者：Thi Thanh Binh Nguyen、Thierry Lomberget、Ngoc Chau Tran、Evelyne Colomb、Lore Nachtergaele、Sylviane Thoret、Joëlle Dubois、Joren Guillaume、Rawad Abdayem、Marek Haftek、Roland Barret

  DOI：10.1016/j.bmcl.2012.09.047

  日期：2012.12

  A novel series of combretastatin A-4 heterocyclic analogues was prepared by replacement of the B ring with indole, benzofurane or benzothiophene, attached at the C2 position. These compounds were evaluated for their abilities to inhibit tubulin assembly: derivative cis 3b, having a benzothiophene, showed an activity similar to those of colchicine or deoxypodophyllotoxine. The antiproliferative and antimitotic properties of cis 3b against keratinocyte cancer cell lines were also evaluated and the intracellular organization of microtubules in the cells after treatment with both stereoisomers of 3b was also determined, using confocal microscopy. (C) 2012 Elsevier Ltd. All rights reserved.
• [EN] METHODS OF PROTECTING AGAINST NEURODEGENERATION<br/>[FR] PROCÉDÉS DE PROTECTION CONTRE LA NEURODÉGÉNÉRESCENCE
  申请人：BIOVENTURES LLC

  公开号：WO2018144910A1

  公开（公告）日：2018-08-09

  The disclosure provides a method of preventing or reducing protein aggregates using combretastatin-A4 (CA4) or an analog thereof. The disclosure also provides methods of reducing the risk, delaying the onset, delaying or slowing the progression, or reversing the signs or symptoms of a neurodegenerative (or other age-progressive) disease using a combretastatin-A4 (CA4) or an analog thereof. The combretastatin-A4 (CA4) or an analog thereof may bind glial fibrillary acidic protein (GFAP). The combretastatin-A4 (CA4) or an analog thereof is described by compounds of Formula (I).